BDNF and Stroke: Altogether, these pathological mechanisms lead to abnormal BDNF/TrkB-signaling which contributes to excitotoxicity, pointing to TrkB-FL and TrkB-T1 as relevant therapeutic targets for treatment of stroke and excitotoxicity-associated pathologies.